Phase 1b/2 Study to Evaluate Safety, Efficacy,
Pharmacokinetics and Pharmacodynamics of Erdafitinib plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with Selected FGFR Gene Alterations, NCT03473743
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
The purpose of this study is to identify the recommended Phase 2 dose (RP2D) and schedule of erdafitinib in combination with JNJ-63723283 (Phase 1b) and to evaluate the safety and clinical activity of erdafitinib alone and in combination with JNJ-63723283 (Phase 2).
MORE DETAILS ON THIS TRIAL
17165 / NCT03480646 / Call PM 4-30-2018